152 related articles for article (PubMed ID: 29190505)
1. Advances in sarcoma gene mutations and therapeutic targets.
Gao P; Seebacher NA; Hornicek F; Guo Z; Duan Z
Cancer Treat Rev; 2018 Jan; 62():98-109. PubMed ID: 29190505
[TBL] [Abstract][Full Text] [Related]
2. Advances in sarcoma diagnostics and treatment.
Dancsok AR; Asleh-Aburaya K; Nielsen TO
Oncotarget; 2017 Jan; 8(4):7068-7093. PubMed ID: 27732970
[TBL] [Abstract][Full Text] [Related]
3. Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-
Xia Y; Wang L; Ma X; Li X
Hum Gene Ther; 2020 Aug; 31(15-16):881-890. PubMed ID: 32013587
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in sarcomas.
Je EM; An CH; Yoo NJ; Lee SH
APMIS; 2012 Aug; 120(8):635-9. PubMed ID: 22779686
[TBL] [Abstract][Full Text] [Related]
6. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
7. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
8. Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience.
Cote GM; He J; Choy E
Oncologist; 2018 Feb; 23(2):234-242. PubMed ID: 28860410
[TBL] [Abstract][Full Text] [Related]
9. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?
Riedel RF
Semin Oncol; 2011 Oct; 38 Suppl 3():S30-42. PubMed ID: 22055970
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy.
Li L; Eid JE; Paz AC; Trent JC
BioDrugs; 2017 Oct; 31(5):379-392. PubMed ID: 28840584
[TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
12. The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development.
Rubio R; Gutierrez-Aranda I; Sáez-Castillo AI; Labarga A; Rosu-Myles M; Gonzalez-Garcia S; Toribio ML; Menendez P; Rodriguez R
Oncogene; 2013 Oct; 32(41):4970-80. PubMed ID: 23222711
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.
Ganjavi H; Gee M; Narendran A; Freedman MH; Malkin D
Cancer Gene Ther; 2005 Apr; 12(4):397-406. PubMed ID: 15618970
[TBL] [Abstract][Full Text] [Related]
14. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic targets in soft tissue sarcoma.
Demicco EG; Maki RG; Lev DC; Lazar AJ
Adv Anat Pathol; 2012 May; 19(3):170-80. PubMed ID: 22498582
[TBL] [Abstract][Full Text] [Related]
16. p53 gene mutations and abnormal retinoblastoma protein in radiation-induced human sarcomas.
Brachman DG; Hallahan DE; Beckett MA; Yandell DW; Weichselbaum RR
Cancer Res; 1991 Dec; 51(23 Pt 1):6393-6. PubMed ID: 1933904
[TBL] [Abstract][Full Text] [Related]
17. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.
Groisberg R; Roszik J; Conley A; Patel SR; Subbiah V
Curr Oncol Rep; 2017 Oct; 19(12):78. PubMed ID: 29030741
[TBL] [Abstract][Full Text] [Related]
18. Advances in sarcoma genomics and new therapeutic targets.
Taylor BS; Barretina J; Maki RG; Antonescu CR; Singer S; Ladanyi M
Nat Rev Cancer; 2011 Jul; 11(8):541-57. PubMed ID: 21753790
[TBL] [Abstract][Full Text] [Related]
19. Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency.
Choi J; Curtis SJ; Roy DM; Flesken-Nikitin A; Nikitin AY
Am J Pathol; 2010 Nov; 177(5):2645-58. PubMed ID: 20864684
[TBL] [Abstract][Full Text] [Related]
20. Preclinical experimental therapeutic approaches in soft tissue sarcoma.
Hunt KK; Feig BW
Semin Surg Oncol; 1999; 17(1):78-82. PubMed ID: 10402641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
